- 500 mg/5 ml vial (IV)

- 500 mg tablets (PO) and 100 mg/ml oral solution (PO)

Executive Summary

(June 22, 2023)

Executive Summary

Levetiracetam (LEV) is a second generation antiepileptic drug (AED) that has gained popularity in the ED for the treatment of status epilepticus (with a conjunction of benzodiazepines, usually IV lorazepam or IM midazolam)(3, 7); 

Adult dose for status epilepticus (7, 12)

Adult dose for post-traumatic seizure prophylaxis in severe TBI (4, 22)

Adult dose

Adult dose for status epilepticus (7, 12)

Adult dose for post-traumatic seizure prophylaxis in severe TBI (4, 22)

*The dosing strategy may be discussed with the consulting neurologist considering the age and weight of the patient.

Pediatric dose

Pediatric dose for status epilepticus (12, 13, 14)


US FDA-Labeled (21)


Advantages of levetiracetam in the ED

Levetiracetam and TBI seizure prophylaxis new!

Post-traumatic seizures (PTS)

Standard of care and the use of LEV

LEV dosing for PTS


Pregnancy and Lactation


Prolonged experience with levetiracetam in pregnant women has not identified a drug-associated risk of major birth defects or miscarriage, based on published literature, which includes data from pregnancy registries, and reflects experience over two decades (21). 



® 2023 EMDrugs. All rights reserved.



This website provides general information and discussion about medications, health, and related subjects. The words and other con­tent pro­vided in this website, and in any linked mate­ri­als, are not intended and should not be con­strued as med­ical advice. If the reader or any other per­son has a med­ical con­cern, he or she should con­sult with an appropriately-licensed physi­cian or other legally accredited health care worker in the country that resides or is visiting. 


Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations. 


The views expressed on this blog and web­site have no rela­tion to those of any academic, hospital, practice or other insti­tu­tion with which the authors are  affiliated. 


For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.

EMDrugs Team